A naturalistic evaluation and audit database of agomelatine: Clinical outcome at 12 weeks

Acta Psychiatrica Scandinavica

Volumn 128, Issue 3, 2013, Pages 203-211

  Sparshatt, A ^a,b   Mcallister Williams, R H ^c   Baldwin, D S ^d   Haddad, P M ^e,f   Bazire, S ^g   Weston, E ^h   Taylor, P ⁱ   Taylor, D ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g NORFOLK AND SUFFOLK NHS FOUNDATION TRUST   (United Kingdom)

^h LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

ⁱ Insights in Healthcare   (United Kingdom)

Author keywords

Adverse effects; Agomelatine; Depression; Effectiveness

Indexed keywords

AGOMELATINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; AGGRESSION; ANXIETY; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COMORBIDITY; CONCENTRATION LOSS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERPHAGIA; IRRITABILITY; JAUNDICE; KIDNEY DYSFUNCTION; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; RASH; RELAPSE; RESTLESSNESS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SUNBURN; SWELLING; TASTE DISORDER; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ADVERSE EFFECTS; AGOMELATINE; DEPRESSION; EFFECTIVENESS;

ACETAMIDES; ADULT; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE; FEMALE; GREAT BRITAIN; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84881552498     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12044     Document Type: Article

References (14)

1. World Health Organisation. Depression. 2012. http://www.who.int/mental_health/management/depression/definition/en/index.html.
2. National Institute for Clinical Excellence. Depression: the treatment and management of depression in adults (update). CG90. 2009. http://www.nice.org.uk/.
3. Sansone Ra, Sansone La. Agomelatine: a novel antidepressant. Innov Clin Neurosci 2011;8:10-14.
4. Stahl Sm. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol 2007;10:575-578.
5. Racagni G, Riva Ma, Molteni R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011;12:574-587.
6. Kennedy Sh, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-333.
7. Kasper S, Lemoine P. Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline. Eur Neuropsychopharmacol 2008;18:S331-S332.
8. Servier Laboratories Limited. Summary of product characteristics: valdoxan 25 mg film-coated tablets. 2012. http://www.medicines.org.uk/EMC/medicine/21830/SPC/Valdoxan/.
9. Singh Sp, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011; August 23: 1-12.
10. Laux G. The antidepressant efficacy of agomelatine in daily practice: Results of the non-interventional study VIVALDI. Eur Psychiatry 2011;26(Suppl 1):647.
11. Guy W. The clinical global impressions scale. In: Guy W, ed. ECDEU assessment manual for psychopharmacology rev ed. Rockville, MD: National Institute of Mental Health, 1976:157-169.
12. Taylor Dm, Young C, Patel Mx. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2006;9:685-694.
13. Taylor D, Atkinson J, Fischetti C, Sparshatt A, Jones S. A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome. Acta Psychiatr Scand 2007;116:461-466.
14. Dunner Dl, Rush Aj, Russell Jm, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006;67:688-695.